^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclophosphamide

    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    11h
    Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) (clinicaltrials.gov)
    P2, N=145, Not yet recruiting, St. Jude Children's Research Hospital
    New P2 trial
    |
    Venclexta (venetoclax) • dasatinib • cytarabine • bortezomib • cyclophosphamide • vincristine • daunorubicin • nelarabine • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine
    11h
    Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 (clinicaltrials.gov)
    P1, N=37, Recruiting, AvenCell Europe GmbH | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    CD123 expression
    |
    cyclophosphamide • fludarabine IV • AVC-201
    11h
    Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (clinicaltrials.gov)
    P3, N=478, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open • Surgery
    |
    ALK (Anaplastic lymphoma kinase) • TERT (Telomerase Reverse Transcriptase) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane
    14h
    Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma (clinicaltrials.gov)
    P2, N=137, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Mar 2024
    Trial completion • Trial completion date • Combination therapy
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Xalkori (crizotinib) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • Adcetris (brentuximab vedotin) • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    1d
    Kinetics of Recovery of Naïve and Memory T Cells in Acute Leukemia Patients after Allogeneic Stem Cell Transplantation Depending on Different GVHD Prophylaxis Regimens. (PubMed, Int J Hematol Oncol Stem Cell Res)
    These experimental outcomes contribute to providing the best understanding of immunological events that occur early after transplantation and help in the rational choice of GVHD prophylaxis in patients who will undergo allogeneic transplantation. Our study demonstrated the comparable immunological effects of posttransplant cyclophosphamide and ex vivo T cell depletion and immunological inefficiency of horse ATG for GVHD prevention.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    cyclophosphamide
    1d
    Nephroprotective Effect of Bergapten Against Cyclophosphamide-Mediated Renal Stress, Inflammation, and Fibrosis in Wistar Rats: Probable Role of NF-kB and TGF-β1 Signaling Molecules. (PubMed, ACS Omega)
    We found that BGP-10 effectively reversed the damage toward normal, whereas BGP-3 failed to exhibit a significant renal protective effect. We conclude that bergapten could be a potential renal protective drug, and hence, more detailed cellular molecular-based studies are needed to bring this drug from the bench to the bedside.
    Preclinical • Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • CEACAM1 (CEA Cell Adhesion Molecule 1)
    |
    cyclophosphamide
    1d
    PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2024 --> Dec 2024
    Trial completion date • CAR T-Cell Therapy • Metastases
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    cyclophosphamide • fludarabine IV • MB-105
    1d
    DESTINY-Breast11: Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer (clinicaltrials.gov)
    P3, N=912, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • doxorubicin hydrochloride • cyclophosphamide • Herzuma (trastuzumab-pkrb)
    1d
    Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors. (clinicaltrials.gov)
    P1, N=134, Completed, Peking University | Recruiting --> Completed
    Trial completion • CAR T-Cell Therapy • Metastases
    |
    CLDN18 (Claudin 18)
    |
    Loqtorzi (toripalimab-tpzi) • cyclophosphamide • satricabtagene autoleucel (CT041)
    1d
    To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer (clinicaltrials.gov)
    P2, N=79, Not yet recruiting, RemeGen Co., Ltd.
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • cyclophosphamide • epirubicin • Aidixi (disitamab vedotin)
    1d
    CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=24, Recruiting, Marcela V. Maus, M.D.,Ph.D. | Trial completion date: Oct 2027 --> Jan 2028 | Trial primary completion date: Oct 2025 --> Jan 2027
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD79B (CD79b Molecule)
    |
    cyclophosphamide • fludarabine IV
    1d
    High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Indiana University | N=72 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Post-transplantation
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    bortezomib • cyclophosphamide
    1d
    Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=66, Recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: May 2028 --> May 2025
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
    |
    CD20 expression • CD22 positive
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • mercaptopurine • dexamethasone injection
    1d
    Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL (clinicaltrials.gov)
    P3, N=81, Recruiting, First Affiliated Hospital of Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • cytarabine • cyclophosphamide • daunorubicin • Synribo (omacetaxine mepesuccinate) • vindesine
    1d
    Augmentation of NK-cell activity and immunity by combined natural polyphenols and saccharides in vitro and in vivo. (PubMed, Int J Biol Macromol)
    The present study was designed to systematically elucidate the in vitro and in vivo immuno-enhancing effects of a combination of C. longa and S. coreanum extracts (CS) that contain polyphenols and saccharides as functional molecules in a cyclophosphamide (Cy)-induced model of immunosuppression...These results suggest that CS treatment accelerates the amelioration of immune deficiency in Cy-treated primary splenocytes and rats, which supports considering it for immunity maintenance. Our findings provide experimental evidence for further research and clinical application in immunosuppressed patients.
    Preclinical • Journal
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
    |
    cyclophosphamide
    3d
    Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects. (PubMed, Cell Transplant)
    Patients received lymphodepleting chemotherapy with fludarabine and cyclophosphamide before CAR T cell therapy. Progression-free and overall survival were higher in patients with Grades 3-4 persistent cytopenia than in those without cytopenia. Therefore, persistent cytopenia after anti-CD19 CAR T cell therapy in patients with R/R DLBCL can predict therapeutic efficacy and AEs, allowing clinicians to determine the efficiency of CD-19 CAR T cell therapy and the associated AEs.
    Journal • Adverse events
    |
    IL6 (Interleukin 6)
    |
    cyclophosphamide • fludarabine IV
    3d
    Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma. (PubMed, Hematol Oncol)
    The HD-AraC (high-dose cytarabine) regimen was the main first-line induction regimen for younger HBsAg+ patients, and cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) were used for elderly patients. HBsAg seropositivity was associated with a significantly shorter PFS than HBsAg seronegativity when patients were treated with rituximab or CHOP-based regimens...Among the 74 patients who underwent targeted deep sequencing (TDS), the nonsynonymous mutation load of HBsAg+ MCL patients was greater than that of HBsAg- MCL patients. HDAC1, TRAF5, FGFR4, SMAD2, JAK3, SMC1A, ZAP70, BLM, CDK12, PLCG2, SMO, TP63, NF1, PTPR, EPHA2, RPTOR and FIP1L1 were significantly enriched in HBsAg+ MCL patients.
    Clinical data • Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • NF1 (Neurofibromin 1) • FGFR4 (Fibroblast growth factor receptor 4) • CDK12 (Cyclin dependent kinase 12) • PLCG2 (Phospholipase C Gamma 2) • FIP1L1 (Factor Interacting With PAPOLA And CPSF1) • JAK3 (Janus Kinase 3) • HDAC1 (Histone Deacetylase 1) • TP63 (Tumor protein 63) • SMAD2 (SMAD Family Member 2) • SMC1A (Structural Maintenance Of Chromosomes 1A)
    |
    BLM mutation • JAK3 mutation
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine
    4d
    OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine (clinicaltrials.gov)
    P3, N=1152, Completed, Universität des Saarlandes | Active, not recruiting --> Completed | Trial completion date: May 2025 --> Jan 2024 | Trial primary completion date: May 2025 --> Jan 2024
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • FDG PET
    |
    ALK (Anaplastic lymphoma kinase) • CD20 (Membrane Spanning 4-Domains A1)
    |
    ALK positive
    |
    Rituxan (rituximab) • cyclophosphamide • Marqibo (vincristine liposomal)
    5d
    Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=18, Recruiting, Mayo Clinic | Trial completion date: Apr 2025 --> Oct 2025 | Trial primary completion date: Apr 2024 --> Oct 2024
    Trial completion date • Trial primary completion date
    |
    MUC1 (Mucin 1)
    |
    MUC1 expression
    |
    cyclophosphamide
    5d
    Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL (clinicaltrials.gov)
    P2, N=53, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Venclexta (venetoclax) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • mercaptopurine
    5d
    CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    FOLH1 expression
    |
    cyclophosphamide • fludarabine IV • CART-PSMA- TGFβRDN cells
    5d
    Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=50, Suspended, University of Washington | Recruiting --> Suspended
    Trial suspension
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 translocation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • daunorubicin • Polivy (polatuzumab vedotin-piiq) • Neupogen (filgrastim)
    5d
    Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P1, N=27, Completed, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active, not recruiting --> Completed
    Trial completion • Post-transplantation
    |
    cyclophosphamide
    5d
    A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Zhejiang University
    New P1 trial
    |
    CD70 (CD70 Molecule)
    |
    cyclophosphamide
    5d
    NCI-2018-01607: Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=74, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    FLT3 positive
    |
    sorafenib • cyclophosphamide • fludarabine IV • busulfan • Neupogen (filgrastim)
    5d
    RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis (clinicaltrials.gov)
    P1/2, N=12, Not yet recruiting, Cabaletta Bio | Trial completion date: Jul 2028 --> Sep 2029 | Initiation date: May 2024 --> Aug 2024 | Trial primary completion date: Jul 2028 --> Sep 2029
    Trial completion date • Trial initiation date • Trial primary completion date • CAR T-Cell Therapy
    |
    cyclophosphamide
    5d
    Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies (clinicaltrials.gov)
    P1/2, N=54, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    cyclophosphamide • decitabine • fludarabine IV
    6d
    IGNYTE-ESO: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (clinicaltrials.gov)
    P2, N=103, Active, not recruiting, Adaptimmune | Trial primary completion date: Nov 2022 --> Aug 2024
    Trial primary completion date • Combination therapy
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
    |
    HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive
    |
    cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
    6d
    Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (clinicaltrials.gov)
    P2, N=171, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2024 --> Jul 2024
    Trial initiation date • Combination therapy
    |
    MCL1 (Myeloid cell leukemia 1) • KMT2A (Lysine Methyltransferase 2A) • BCL2L1 (BCL2-like 1)
    |
    BCL2 expression
    |
    Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (recombinant Erwinia asparaginase) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    6d
    Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) (clinicaltrials.gov)
    P2, N=154, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2024 --> Aug 2024
    Trial initiation date
    |
    Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • navitoclax (ABT 263) • Oncaspar liquid (pegaspargase) • nelarabine • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    6d
    Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. (PubMed, J Hematol Oncol)
    These data, representing the longest follow-up of BCMA-redirected CAR T-cell therapy to date, demonstrate long-term remission and survival with LCAR-B38M for advanced myeloma.
    Journal • CAR T-Cell Therapy
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    cyclophosphamide • fludarabine IV • Carvykti (ciltacabtagene autoleucel)
    6d
    Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. (PubMed, Nat Cancer)
    In this prospective, interventional phase 1 study for individuals with advanced sarcoma, we infused autologous HER2-specific chimeric antigen receptor T cells (HER2 CAR T cells) after lymphodepletion with fludarabine (Flu) ± cyclophosphamide (Cy): 1 × 108 T cells per m2 after Flu (cohort A) or Flu/Cy (cohort B) and 1 × 108 CAR+ T cells per m2 after Flu/Cy (cohort C). Our results affirm HER2 as a CAR T cell target and demonstrate the safety of this therapeutic approach in sarcoma. ClinicalTrials.gov registration: NCT00902044 .
    P1 data • Journal • CAR T-Cell Therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    cyclophosphamide • fludarabine IV
    6d
    A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
    P3, N=680, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2024 --> Jul 2024
    Trial initiation date
    |
    ABL1 (ABL proto-oncogene 1) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • CD19 (CD19 Molecule) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CSF1R (Colony stimulating factor 1 receptor)
    |
    CD19 expression
    |
    TruSight RNA Pan-Cancer Panel
    |
    dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)
    7d
    Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances (clinicaltrials.gov)
    P1/2, N=48, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD5 (CD5 Molecule)
    |
    cyclophosphamide • fludarabine IV
    7d
    Exploration of the underlying mechanism of Astragaloside III in attenuating immunosuppression via network pharmacology and vitro/vivo pharmacological validation. (PubMed, J Ethnopharmacol)
    In this study, the main targets of AS-III for immunosuppressive therapy were initially analyzed. AS-III was systematically confirmed to attenuates immunosuppressive state through the HIF-1α/PDHK-1 pathway. These findings offer an experimental foundation for the use of AS-III as a potential candidate for the treatment of immunosuppression.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • TNFA (Tumor Necrosis Factor-Alpha) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • IL1B (Interleukin 1, beta) • SLC2A1 (Solute Carrier Family 2 Member 1)
    |
    cyclophosphamide
    7d
    A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020 (clinicaltrials.gov)
    P1, N=20, Recruiting, Vall d'Hebron Institute of Oncology | Trial completion date: Apr 2025 --> Apr 2027 | Trial primary completion date: Sep 2024 --> Sep 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CASP3 (Caspase 3)
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • cyclophosphamide
    8d
    Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker (clinicaltrials.gov)
    P1, N=16, Terminated, AvenCell Europe GmbH | N=51 --> 16 | Trial completion date: Jul 2025 --> Mar 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Mar 2024; Although IMP has been well tolerated, biological activity was very limited. The sponsor concluded that continued development of IMP would be unlikely to result in meaningful clinical benefit for patients with prostate cancer.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy
    |
    cyclophosphamide • fludarabine IV
    8d
    LITMMUS-UCSF: Liver Transplantation With Tregs at UCSF (clinicaltrials.gov)
    P1/2, N=42, Terminated, National Institute of Allergy and Infectious Diseases (NIAID) | N=30 --> 42
    Enrollment change
    |
    everolimus • cyclophosphamide
    8d
    Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC (clinicaltrials.gov)
    P1/2, N=33, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    CSPG4 (Chondroitin Sulfate Proteoglycan 4)
    |
    cyclophosphamide • fludarabine IV
    8d
    Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System (clinicaltrials.gov)
    P3, N=70, Completed, Children's Oncology Group | Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Mar 2024
    Trial completion • Trial completion date • Surgery
    |
    cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • leucovorin calcium • thiotepa • Neupogen (filgrastim)
    8d
    NK4AML: Natural Killer-cell Therapy for Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=23, Recruiting, Radboud University Medical Center | Trial completion date: Sep 2023 --> Sep 2025 | Trial primary completion date: Sep 2023 --> Sep 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    IL2 (Interleukin 2)
    |
    cyclophosphamide • Proleukin (aldesleukin) • oNKord (inaleucel)
    8d
    A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Takeda
    New P1 trial
    |
    cyclophosphamide • TAK-007